In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide PTH 1-84 (parathyroid hormone) | Natural peptide Calcitonin-salmon | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Natural peptide | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 418 | 661 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 48 (34 in people) | 58 (58 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 315 more mention it but do not test it | 18 · 1 active7 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Natpara says: “Adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism” No central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | PTH 1-84 (parathyroid hormone) | Calcitonin-salmon |
|---|---|---|
| Bone and jointMusculoskeletal | 292154138 | 3613464 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Calcitonin salmon nasal spray says: “Postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable”
| Adverse eventsWhole body | 30264 | 4242 |
|---|
| PharmacokineticsPharmacology | 981 | 4949 |
|---|
| PainMusculoskeletal | 11 | 5252 |
|---|
| Electrolyte balanceEndocrine and hormones | 31292 | 1515 |
|---|
| Exercise and physical functionMusculoskeletal | 77 | 2828 |
|---|
| Receptor activity and mechanismKidney and urinary | 11 | 331221 |
|---|
| Calcium MetabolismEndocrine and hormones | 77 | 1111 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 33 | 1313 |
|---|
| Quality of lifeWhole body | 1212 | 44 |
|---|
| Kidney functionKidney and urinary | 1091 | 66 |
|---|
| Glycemic controlMetabolic and weight | 44 | 651 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 31 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Takeda407 participantsJul 2006 to Aug 2011
Osteoporosis
Shire124 participants18 Dec 2008 to 28 Sept 2011
Hypoparathyroidism
Shire93 participants24 Jan 2018 to 19 May 2022
Hypoparathyroidism
5 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 18 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Nordic Bioscience A/S1,030 participantsJun 2008 to Jun 2011
Osteoarthritis
Tarsa Therapeutics, Inc.565 participantsJun 2009 to Feb 2011
Osteoporosis, Postmenopausal
Eli Lilly and Company364 participantsDec 2006 to Jul 2008
Osteoporosis
7 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | PTH 1-84 (parathyroid hormone) | Calcitonin-salmon |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | 7.9% Mean lumbar spine BMD increase at 18 months · PTH(1-84) plus HT Dose studied: 100 microg dailyn not reported2008 | 3% Lumbar BMD change from baseline Dose studied: 200 IU daily, 1 month on-1 month off1 yearn = 912005 |
7.9%
Mean lumbar spine BMD increase at 18 months · PTH(1-84) plus HT
Dose studied: 100 microg dailyn not reported2008
3%
Lumbar BMD change from baseline
Dose studied: 200 IU daily, 1 month on-1 month off1 yearn = 912005
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | PTH 1-84 (parathyroid hormone) | Calcitonin-salmon |
|---|---|---|
| Electrolyte balanceEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | 53% Response · rhPTH(1-84) Placebo: 2% Dose studied: 50 μg per day, titrated to 75 μg or 100 μg24 weeksn = 1342013 |
No comparable result 3 randomized-trial results measure it in another way or another unit. |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 93% Adverse events · rhPTH(1-84) Placebo: 100% Dose studied: 50 μg per day, titrated to 75 μg or 100 μgn = 1342013 | No comparable result 10 randomized-trial results measure it in another way or another unit. |
|---|
53%
Response · rhPTH(1-84)
Placebo: 2%
Dose studied: 50 μg per day, titrated to 75 μg or 100 μg24 weeksn = 1342013
No comparable result
3 randomized-trial results measure it in another way or another unit.
93%
Adverse events · rhPTH(1-84)
Placebo: 100%
Dose studied: 50 μg per day, titrated to 75 μg or 100 μgn = 1342013
No comparable result
10 randomized-trial results measure it in another way or another unit.